Teva's Copaxone display at a recent American Academy of Neurology meeting and a website promoting the multiple sclerosis treatment overstate the drug's safety and efficacy, FDA Office of Prescription Drug Promotion officials said in a letter. Moreover, the website did not include risk information in the text of the Web pages and instead included links to other pages, which the OPDP found misleading.

Full Story:

Related Summaries